Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
about
Anaplastic lymphoma kinase: signalling in development and diseaseEmerging importance of ALK in neuroblastomaEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Activating mutations in ALK provide a therapeutic target in neuroblastoma.ALK and NSCLC: Targeted therapy with ALK inhibitorsT-cell lymphomas, a challenging disease: types, treatments, and future.The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.Research progresses in the pathogenesis of anaplastic large cell lymphoma.ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencingUnique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Myc proteins as therapeutic targets.The receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning.Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis.The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritisAssociation of Zinc Finger, C3HC-Type Containing 1 (ZC3HC1) rs11556924 Genetic Variant With Hypertension in a Finnish Population, the TAMRISK Study.Association of genetic variants with atrial fibrillation.Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOSThe oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Inhibition of Rac controls NPM-ALK-dependent lymphoma development and disseminationAn integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors.Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase.ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomasAnaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entityAnaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.New insights into the genetics of neuroblastoma.Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming
P2860
Q24312329-F0BEEF0C-E468-45C1-A846-54E4F5014887Q26858819-CF0AACA4-9CE1-4BD7-A07F-72FE8F46AB85Q27851440-E6F24B57-42AD-47E0-BBBF-66AC9D40E512Q27851452-DD7B6035-6B8E-41A5-9F16-02BCDC4A813DQ28393324-17274B5B-D7EC-4584-A8B4-8A96D7FF3B69Q30244553-D505FEC0-AFD4-4066-9CC3-0842216F67C9Q30484934-EECD0995-D22E-45CB-9968-F236EDAF9147Q33487136-5C4A1C4E-392D-4FDB-B553-D9CB4CCF04A8Q33579708-70D6A769-DF9C-42F0-BDB5-3800D67A20C7Q33707493-2672568E-BF40-47FD-98E9-737429052812Q33732485-0718F4AE-DFD9-4272-A94E-3C482F3F7E51Q33833942-756970CB-2F56-4254-910C-E28D5541A5ECQ33997741-E1BAE881-3C8D-4B61-A469-39EF54F271E3Q34031191-ADEC6E5F-13BC-4AC6-BF02-7D19424F724CQ34182453-097E5BEC-DA0D-4A35-AB60-F6F261DE7876Q34388576-6C5A455A-117E-484E-8F7B-5A6DED897FFBQ34489188-ADD12222-B88F-40AE-AF14-E0CAB7D1FBC5Q34514793-F8548561-ADB1-495B-B746-7806EB45B9BAQ35011473-3EE132B1-98E6-4A7C-802A-43CEDBFA3EF2Q35013574-12D1881A-0E73-4EA8-A1A9-A4C3E0CEB7E3Q35123227-998C1F2F-AEDC-4D98-8537-D56108327F00Q35220408-FA22AF74-102C-491A-A453-2633C7029F12Q35607281-167A679E-1466-43C2-8ECD-21D754EE318AQ35664324-FAC410CD-3E0F-4AFD-96A0-1E8B94674842Q35892197-4A3F520B-C669-45E7-BB72-4512BDB67463Q36058634-34966791-A8CD-4FAA-BEF6-641C1CF40933Q36477122-79472FB7-0D00-48DB-B155-EAB957CCBBEEQ37081609-504E4BD9-D6D3-4E4D-96E4-E24E558BDA26Q37130122-BF4B5B43-C0B7-4ED5-88C5-D8AE2DEF1174Q37268913-0AF6D678-40D6-45C5-9A83-D186E80B80CFQ37411178-230F72C1-7E7E-42DC-9291-EA3DB7ABD387Q37996424-57885442-4915-4D48-A39E-503B6F37C0B3Q38010052-F78C1C04-03A2-43B0-B756-DE91EDD0996AQ38074590-48E4740E-43A2-4631-8C81-DDA72B7C693FQ38074875-23EF32B2-BFBA-4F8C-A6AF-C3421C4A4B2DQ38132359-53283073-B19A-4D65-8AD5-996C35F20485Q38307616-CA54EFB4-FE12-4705-90ED-923EB9EE49E8Q38386866-25730B7E-A2AF-403A-9137-24A1C52CC156Q38771110-2A8439F4-0DFF-4E31-90AE-2D307FA7C744Q39064213-B62C9A55-5773-4DD5-B6CA-64C81C2C8FB6
P2860
Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@ast
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@en
Development of anaplastic lymphoma kinase
@nl
type
label
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@ast
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@en
Development of anaplastic lymphoma kinase
@nl
prefLabel
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@ast
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@en
Development of anaplastic lymphoma kinase
@nl
P2860
P356
P1476
Development of anaplastic lymp ...... inhibitors for cancer therapy.
@en
P2093
Rongshi Li
Stephan W Morris
P2860
P304
P356
10.1002/MED.20109
P577
2008-05-01T00:00:00Z